Dong-A Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1932-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.dapharm.com
Clinical Trials
19
Active:0
Completed:12
Trial Phases
4 Phases
Phase 1:11
Phase 2:2
Phase 3:4
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (57.9%)Phase 3
4 (21.1%)Phase 2
2 (10.5%)Phase 4
2 (10.5%)Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02058472
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT01941199
- Locations
- 🇰🇷
Clinical Trial Center, Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01929213
- Locations
- 🇰🇷
Severance Hospital Clinical Trial Center, Seoul, Korea, Republic of
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine
Phase 1
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT01928563
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Phase 4
Completed
- Conditions
- Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 411
- Registration Number
- NCT01922375
- Locations
- 🇰🇷
Chonnam national university hospital, Gwangju, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found